Why Is SELLAS Life Sciences Group (SLS) Stock Down -5.65% Today?
Key Takeaways
- SLS shares fell approximately 5.65% on Monday, extending Friday's 8.27% decline and marking a two-session drop of roughly 13.5%.
- Martin Shkreli's public skepticism about the timing and probability of success for the Phase 3 REGAL trial intensified selling pressure.
- Institutional unwinding — Vision Financial Markets disclosed a 97% reduction in its SLS stake — rattled confidence among retail and momentum-driven traders.
- Profit-taking after a massive year-long rally (up over 500% year-over-year and roughly 200% year-to-date) added to downward momentum.
- The stock's decline was company-specific: the SPDR S&P Biotech ETF (XBI) traded up approximately 0.8% during the same session, confirming the weakness was not sector-wide.
- Traders are now watching for the 80th-event trigger in the REGAL trial, any regulatory or partnership announcements, and whether support levels near $10 hold.
Opening Summary
Shares of SLS — SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company developing novel cancer immunotherapies — fell approximately 5.65% on Monday to trade near $10.68, down from Friday's close of $11.32. The decline extended a sharp sell-off that began late last week, with the stock now down roughly 23% for the month of July. The drop came despite a modestly positive session for the broader biotechnology sector and with no fresh company-specific press releases or SEC filings on the day. Instead, the pressure appeared driven by a combination of high-profile bearish commentary, institutional-position disclosures showing heavy selling, and the unwinding of speculative momentum that had propelled SLS to extraordinary gains over the past twelve months.
Shkreli Criticism Reignites REGAL Trial Doubts
A significant catalyst for Monday's slide was a wave of public skepticism from controversial biotech investor Martin Shkreli, who questioned both the timing and the likelihood of a successful outcome for SELLAS's pivotal Phase 3 REGAL trial. The study, which is evaluating the company's lead candidate galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients, has reached 78 of the 80 patient-death events required to trigger the final analysis. Shkreli's commentary cast doubt on whether the slower-than-expected accumulation of those final two events genuinely reflects a durable survival benefit for GPS — as CEO Angelos Stergiou has suggested — or instead signals selection bias and an inflated probability of success. The remarks reverberated across retail trading platforms where SLS has attracted an ardent following, flipping sentiment bearish and accelerating the exit of momentum-driven positions.
Institutional Selling Undermines Confidence
Adding fuel to the sell-off, newly disclosed institutional-ownership data showed Vision Financial Markets slashed its SLS position by 294,600 shares — a cut of 97% — leaving it with just 9,800 shares as of the end of June. While other funds, including Martin Capital Advisors and EverSource Wealth Advisors, initiated or added modest positions, the headline-grabbing exit by Vision Financial Markets dominated the narrative. For a stock that has been heavily driven by retail enthusiasm and social-media momentum, the appearance of a large institutional seller heading for the exits was enough to shake fragile confidence and prompt additional de-risking.
Profit-Taking After a Monumental Rally
Monday's drop also reflects the gravitational pull of profit-taking following an extraordinary rally. SLS had surged more than 500% over the trailing twelve months and approximately 200% year-to-date, catapulting the company's market capitalization from roughly $73 million at the start of 2024 to over $2 billion by mid-2026. With the REGAL readout still pending but the company now operating under a self-imposed quiet period — during which no clinical updates will be issued — many traders who rode the stock higher appear to be locking in gains rather than holding through an uncertain news vacuum. The absence of any official press releases or SEC filings on Monday left the stock particularly vulnerable to sentiment-driven selling.
Dilution Overhang and Quiet-Period Anxiety
Underlying structural concerns are also weighing on the stock. SELLAS's outstanding share count has nearly doubled over the past year, rising from approximately 99.8 million shares in May 2025 to 196.6 million by June 2026 — a roughly 97% increase that has significantly diluted existing shareholders. The company also maintains a $150 million at-the-market equity offering program, which, while not yet utilized as of its last update, represents a persistent overhang. Meanwhile, CEO Stergiou's confirmation that the company has entered a quiet period ahead of the REGAL database lock means investors face an information vacuum that could last weeks. For a high-beta biotech name heavily reliant on news flow to sustain elevated valuations, that silence is itself a source of pressure.
Market Context and Trading Activity
Monday's decline was notably company-specific. The SPDR S&P Biotech ETF (XBI) advanced roughly 0.8% during the session, and the iShares Biotechnology ETF (IBB) also traded in positive territory, confirming that SLS was moving against the sector tide. Trading volume surpassed 7 million shares, roughly in line with or slightly below the stock's elevated average, but the intraday price range was extreme — spanning from a low of $9.60 to a high of $11.89, representing a swing of approximately 20% relative to Friday's close, before the stock partially recovered into the $10.60–$10.70 zone. The $9.60 intraday low marked the stock's deepest trough since late June, testing a critical psychological support level that traders are now closely monitoring.
What Comes Next for SLS
The immediate focus for SLS remains squarely on the REGAL trial's 80th-event trigger and the subsequent topline data readout. With 78 events confirmed as of mid-May and no official update since, the announcement could arrive at any time — and it will almost certainly define the stock's trajectory for the remainder of 2026. Beyond REGAL, investors are also tracking the Phase 2 trial of SLS009 (tambiciclib), the company's CDK9 inhibitor in newly diagnosed AML patients, with topline data expected in the fourth quarter. Risks include the binary nature of the REGAL outcome — where failure would put a substantial portion of the company's enterprise value at risk — as well as continued share dilution and the possibility that the quiet period extends longer than the market anticipates. On the upside, a successful GPS readout could transform SELLAS from a clinical-stage biotech into a commercial-ready oncology company, potentially attracting partnership or acquisition interest from major pharmaceutical players.
Trending AI Robots
For traders seeking to navigate volatile names like SLS with greater discipline, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to shifting market conditions. Tickeron hosts hundreds of algorithmic trading bots covering thousands of tickers across multiple strategies, timeframes, and performance metrics — but only the strongest performers under current conditions are featured in the Trending AI Robots section. Whether you favor momentum strategies, swing-trading approaches, or mean-reversion tactics, exploring the Trending AI Robots page can help you identify data-driven systems aligned with today's market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SLS in downward trend: 10-day moving average broke below 50-day moving average on September 18, 2026
The 10-day moving average for SLS crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SLS turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 36 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
SLS moved below its 50-day moving average on September 11, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
SLS broke above its upper Bollinger Band on September 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SLS entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 58 cases where SLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on SLS as a result. In 76 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
Following a +1.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 242 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.007) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals
Industry Biotechnology
Advertisement